This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Alterity Therapeutics Reveals Top Option HoldersApril 21, 2025 | tipranks.comAlterity Therapeutics completes placementApril 9, 2025 | uk.investing.comAlterity Therapeutics announces regulatory noticeApril 9, 2025 | uk.investing.comAlterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual MeetingApril 3, 2025 | markets.businessinsider.comAlterity Therapeutics completes last patient visit in ATH434-202 Phase 2 trialMarch 28, 2025 | markets.businessinsider.comAlterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to BillionairesMarch 10, 2025 | msn.comAlterity Therapeutics Ltd PBNMarch 1, 2025 | morningstar.comAlterity Therapeutics Expands Capital with New Securities QuotationFebruary 18, 2025 | tipranks.comAlterity Therapeutics to List New Securities on ASXFebruary 16, 2025 | tipranks.comAlterity secures funding to advance MSA drug developmentFebruary 10, 2025 | msn.comAlterity Therapeutics raises A$40M in placementFebruary 10, 2025 | markets.businessinsider.comAlterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 yearFebruary 8, 2025 | finance.yahoo.comAlterity Therapeutics reports compliance with Takeovers PanelFebruary 5, 2025 | msn.comAlterity Therapeutics announces securities noticeFebruary 4, 2025 | msn.comAlterity Therapeutics Completes Significant Share IssuanceFebruary 3, 2025 | tipranks.comAlterity Therapeutics announces ATH434 Phase 2 trial resultsJanuary 30, 2025 | msn.comAlterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement SoarsJanuary 30, 2025 | msn.comAlterity Therapeutics price target raised to $12 from $8 at MaximJanuary 30, 2025 | markets.businessinsider.comAlterity Therapeutics Ltd (ADR) trading halted, news pendingJanuary 27, 2025 | markets.businessinsider.comAlterity Therapeutics reports cash balance of A$4.54M as of December 31January 24, 2025 | markets.businessinsider.comAlterity Therapeutics reports quarterly activitiesJanuary 24, 2025 | msn.comAlterity CEO says ‘filled with optimism for 2025’January 10, 2025 | markets.businessinsider.comAlterity Therapeutics Alerts Investors on Potential RisksNovember 23, 2024 | markets.businessinsider.comAlterity Therapeutics Advances Amid Successful AGMNovember 22, 2024 | markets.businessinsider.comAlterity Therapeutics Advances in Neurodegenerative Drug TrialsNovember 21, 2024 | markets.businessinsider.comAlterity Therapeutics Appoints New Company SecretaryNovember 19, 2024 | markets.businessinsider.comAlterity Therapeutics appoints Abby Macnish Niven as secretaryNovember 19, 2024 | markets.businessinsider.comAlterity Therapeutics Unveils New Advances for MSA TrackingNovember 12, 2024 | markets.businessinsider.comAlterity Therapeutics announces new publication on ATH434November 6, 2024 | markets.businessinsider.comAlterity Therapeutics: Innovative Approach with ATH434November 6, 2024 | markets.businessinsider.comAlterity Therapeutics Reveals Positive MSA Trial DataOctober 31, 2024 | markets.businessinsider.comAlterity Therapeutics Prepares for 2024 Annual General MeetingOctober 23, 2024 | markets.businessinsider.comAlterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®October 2, 2024 | markets.businessinsider.comAlterity Therapeutics Appoints Abby Macnish Niven To Succeed Phillip Hains As CFOSeptember 30, 2024 | markets.businessinsider.com‘Holy Grail’ – Alterity Therapeutics aims to slow progression of Parkinson’s diseaseSeptember 18, 2024 | msn.comKazia Therapeutics Limited (KZIA)April 18, 2024 | finance.yahoo.comAlterity Therapeutics Says Phillip Hains To Replace Kathryn Andrews As CFODecember 21, 2023 | nasdaq.comAlterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerDecember 21, 2023 | markets.businessinsider.comAlterity jumps after promising data on Parkinson's candidateDecember 4, 2023 | seekingalpha.comWhy Is Alterity Therapeutics (ATHE) Stock Up 150% Today?December 4, 2023 | investorplace.comAxsome Therapeutics Inc AXSMOctober 31, 2023 | morningstar.comADRs End Higher; Orchard Therapeutics PLC Climbs 96%October 8, 2023 | morningstar.comAlterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer'sAugust 23, 2023 | technews.tmcnet.comAlterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's DiseaseMarch 14, 2023 | technews.tmcnet.comAlterity: Study Shows ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal ModelJanuary 30, 2023 | marketwatch.comAlterity Therapeutics Stock (OTC:PRNAF), Analyst Ratings, Price Targets, PredictionsSeptember 26, 2022 | benzinga.comHere's Why Alterity Therapeutics Shares Are VolatileSeptember 20, 2022 | msn.com Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAN Media Mentions By Week PRAN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAN News Sentiment▼0.000.58▲Average Medical News Sentiment PRAN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAN Articles This Week▼01▲PRAN Articles Average Week Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enanta Pharmaceuticals News Today scPharmaceuticals News Today RAPT Therapeutics News Today Contineum Therapeutics News Today Tonix Pharmaceuticals News Today Immunic News Today Virios Therapeutics News Today Procaps Group News Today BioHarvest Sciences News Today Silence Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRAN Stock Free PRAN Stock Alerts